Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing/Gene expression studies of prednisolone in aggressive B-cell lymphomas [JC1]

ABSTRACT: RNA sequencing/Gene expression studies of prednisolone in aggressive B-cell lymphomas [JC1]

PROVIDER: PRJNA941904 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23719454_1.fastq.gz	Fastqsanger.gz
	SRR23719454_2.fastq.gz	Fastqsanger.gz
	SRR23719455_1.fastq.gz	Fastqsanger.gz
	SRR23719455_2.fastq.gz	Fastqsanger.gz
	SRR23719456_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 72

Similar Datasets

RNA sequencing/Gene expression studies of prednisolone in aggressive B-cell lymphomas [JC1]

Project description:We determined that glucocorticoid (prednisolone) treatment affects oncogenic signaling in aggressive B-cell lymphomas. We sought to measure gene expression change in aggressive B-cell lymphoma cells by RNA-sequencing following prednisolone treatment.

2023-03-17 | GSE226862 | GEO

Cleavage Under Targets and Release Using Nuclease (CUT&RUN) assay of glucocorticoid receptor (NR3C1) in aggressive B-cell lymphomas [JC3]

Project description:We determined that glucocorticoid treatment (prednisolone) affects oncogenic signaling in aggressive B-cell lymphomas. We sought to identify genes directly controlled and bound by NR3C1.

2023-03-17 | GSE226873 | GEO

Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas

Project description:Prednisone is anti-inflammatory glucocorticoid (GC), and GC-based therapy is most used combination chemotherapy for treating aggressive B-cell lymphomas. However, there are still gaps in our understanding of specific mechanism of GCâ€™s action for its cytotoxicity. By performing multi-omics approaches, we identified new GR targets and how these targets control the b-cell receptor signaling networks, providing a mechanistic framework upon which to base combination therapies.

2024-05-02 | PXD041891 | Pride

DDX3X Loss is Associated with Aggressive Phenotypes in Non-Hodgkin’s Lymphomas

Project description:DDX3X Loss is Associated with Aggressive Phenotypes in Non-Hodgkin’s Lymphomas

| PRJNA687675 | ENA

RNA sequencing/Gene expression studies of G⍺13 signaling in lymphoma [RNA-seq]

Project description:We determined that loss of G⍺13 signaling promotes oncogenic signaling in aggressive B-cell lymphomas. We sought to measure gene expression change in aggressive B-cell lymphoma cells by RNA-sequencing following G⍺13 stimulation.

2024-01-17 | GSE253433 | GEO

RNA sequencing/Gene expression studies of G⍺13 signaling in lymphoma [scRNA-seq]

Project description:We determined that loss of G⍺13 signaling promotes oncogenic signaling in aggressive B-cell lymphomas. We sought to measure gene expression change in control and G⍺13-deficient germinal center (GC) B cells by RNA-sequencing

2024-01-17 | GSE253434 | GEO

Established cell lines and patient-derived xenografts as equally relevant models of aggressive lymphomas

Project description:Established cell lines and patient-derived xenografts as equally relevant models of aggressive lymphomas

| PRJNA376701 | ENA

Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy

Project description:Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy

| PRJNA945097 | ENA

Transcription profiling of human Burkitts lymphomas

Project description:The distinction between the Burkitt lymphoma and diffuse large B-cell lymphoma is imprecise using current diagnostic criteria. We applied transcriptional and genomic profiling to molecularly define Burkitt lymphoma. Gene expression profiling employing Affymetrix GeneChips (U133A) was performed in 220 mature aggressive B-cell lymphomas, including a core group of eight Burkitt lymphomas, which fulfilled all diagnostic criteria of the WHO classification. A molecular signature of Burkitt lymphoma was generated. Chromosomal abnormalities were detected by interphase fluorescence in-situ hybridization and array comparative genomic hybridization. The molecular Burkitt lymphoma signature identified 44 cases. Fifteen of these cases lacked a morphology typical for Burkitt/Burkitt-like lymphoma. The vast majority (88%) of the 176 lymphomas without the molecular Burkitt lymphoma signature represented diffuse large B-cell lymphomas. In 20% of these cases a MYC break was detectable which was associated with complex chromosomal changes. Our molecular definition of Burkitt lymphoma sharpens and extends the spectrum of Burkitt lymphoma. In mature aggressive B-cell lymphomas without a Burkitt lymphoma signature, a chromosomal break in the MYC locus proved to be associated with adverse clinical outcome. Experiment Overall Design: 220 diffuse large B-cell lymphoma and Burkitt lymphoma samples hybridized to 221 HGU133A Affymetrix GeneChips

2008-06-13 | E-GEOD-4475 | biostudies-arrayexpress

Recurrent 11q aberrations in MYC-neg mature aggressive B-cell lymphomas resembling BL

Project description:Copy number analysis using Agilent 244k or 180k (Case9) arrays was performed for 8 MYC-negative B-cell lymphomas, with sex-matched control DNAs

2014-01-10 | GSE47506 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data